TTD_Target_ID	Target_Name	TTD_Drug_ID	Drug_Name	Drug_Highest_Status	Drug_PubchemID	Molecular_Formula	Molecular_Weight	Canonical_SMILES	Activity	Binder_Type
T82266	Voltage-gated L-type calcium channel	D02MLW	Ibutilide	Approved	60753	C20H36N2O3S	384.6	CCCCCCCN(CC)CCCC(C1=CC=C(C=C1)NS(=O)(=O)C)O	IC50 = 62500 nM	Poor binder
T82266	Voltage-gated L-type calcium channel	D03VPC	Cilostazol	Approved	2754	C20H27N5O2	369.5	C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4	IC50 = 91200 nM	Poor binder
T82266	Voltage-gated L-type calcium channel	D04VMT	Sotalol	Approved	5253	C12H20N2O3S	272.37	CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O	IC50 = 193300 nM	Poor binder
T82266	Voltage-gated L-type calcium channel	D07ACT	Ceftriaxone	Approved	5479530	C18H18N8O7S3	554.6	CN1C(=NC(=O)C(=O)N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)O	IC50 = 153800 nM	Poor binder
T82266	Voltage-gated L-type calcium channel	D07TQV	Lamivudine	Approved	60825	C8H11N3O3S	229.26	C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N	IC50 = 54200 nM	Poor binder
T82266	Voltage-gated L-type calcium channel	D07UYO	Linezolid	Approved	441401	C16H20FN3O4	337.35	CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F	IC50 = 105400 nM	Poor binder
T82266	Voltage-gated L-type calcium channel	D0A2ZX	Metronidazole	Approved	4173	C6H9N3O3	171.15	CC1=NC=C(N1CCO)[N+](=O)[O-]	IC50 = 177900 nM	Poor binder
T82266	Voltage-gated L-type calcium channel	D0B3UJ	Paliperidone	Approved	115237	C23H27FN4O3	426.5	CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F	IC50 = 193900 nM	Poor binder
T82266	Voltage-gated L-type calcium channel	D0E6XR	Dasatinib	Approved	3062316	C22H26ClN7O2S	488	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO	IC50 = 81100 nM	Poor binder
T82266	Voltage-gated L-type calcium channel	D0K6GZ	Sparfloxacin	Approved	60464	C19H22F2N4O3	392.4	C[C@@H]1CN(C[C@@H](N1)C)C2=C(C(=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)N)F	IC50 = 88800 nM	Poor binder
T82266	Voltage-gated L-type calcium channel	D0NW3X	Dofetilide	Approved	71329	C19H27N3O5S2	441.6	CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C	IC50 = 60000 nM	Poor binder
T82266	Voltage-gated L-type calcium channel	D0U2JP	Sitagliptin	Approved	4369359	C16H15F6N5O	407.31	C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N	IC50 = 147100 nM	Poor binder
T82266	Voltage-gated L-type calcium channel	D0X0RI	Mexiletine	Approved	4178	C11H17NO	179.26	CC1=C(C(=CC=C1)C)OCC(C)N	IC50 = 100000 nM	Poor binder
T82266	Voltage-gated L-type calcium channel	BC6N2Y	Ethyl (4S)-5-[2-(1-benzylpiperidin-4-yl)ethylamino]-5-oxo-4-(phenylmethoxycarbonylamino)pentanoate	Investigative	137632867	C29H39N3O5	509.6	CCOC(=O)CC[C@@H](C(=O)NCCC1CCN(CC1)CC2=CC=CC=C2)NC(=O)OCC3=CC=CC=C3	IC50 = 90080 nM	Poor binder
T82266	Voltage-gated L-type calcium channel	BIES75	4-[4-Amino-5-(trifluoromethyl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]-2-[(5S,6R)-2,2,5,6-tetramethyl-3-oxomorpholin-4-yl]benzonitrile	Investigative	137653443	C22H21F3N6O2	458.4	C[C@H]1[C@H](OC(C(=O)N1C2=C(C=CC(=C2)C3=CC(=C4N3N=CN=C4N)C(F)(F)F)C#N)(C)C)C	IC50 ~ 80000 nM	Poor binder
T82266	Voltage-gated L-type calcium channel	BV3JD9	Chembl4172669	Investigative	145950976	C24H33N5	391.6	CN(C[C@H]1CC2=C(CN1)C=CC=C2N3CCNCC3)[C@H]4CCCC5=C4N=CC=C5	IC50 ~ 80000 nM	Poor binder
T82266	Voltage-gated L-type calcium channel	BYP1A4	(18R)-13-Ethyl-8-methyl-8,15-diazahexacyclo[14.2.1.01,9.02,7.010,15.012,17]nonadeca-2,4,6-triene-14,18-diol	Investigative	70691408	C20H26N2O2	326.4	CCC1C2CC3C4C5(CC(C2[C@H]5O)N3C1O)C6=CC=CC=C6N4C	IC50 = 71000 nM	Poor binder